Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer

Published:2020-09-01 Issue:7 Volume:35 Page:485-489
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Dorff Tanya B.¹,Stein Cy¹,Kortylewski Marcin²,Posadas Edwin³,Synold Timothy²,Quinn David⁴

Affiliation:

1. Department of Medical Oncology and Developmental Therapeutics, City of Hope National Medical Center, Duarte, California, USA.

2. Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.

3. Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.

4. Department of Medicine, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/cbr.2019.3397

Reference39 articles.

1. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone

2. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer

3. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

4. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

5. Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune effects of α and β radionuclides in metastatic prostate cancer;Nature Reviews Urology;2024-08-27

2. Role of Tyrosine Kinases and their Inhibitors in Cancer Therapy: A Comprehensive Review;Current Medicinal Chemistry;2023-04

3. Interval Changes in PSMA PET/CT During Radium-223 Therapy for Metastatic Bone Disease from Castration-Resistant Prostate Cancer;Nuclear Medicine and Molecular Imaging;2022-06-08